Pharma Mar SA

As of June 30, 2026, Pharma Mar SA carries a market capitalization of 1.31B, placing it among publicly traded companies globally. Its enterprise value stands at 1.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pharma Mar SA's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Pharma Mar SA has 17.32M shares outstanding.

As of June 30, 2026, Pharma Mar SA trades at a trailing price-to-earnings ratio of 16.51. The price-to-sales ratio is 4.73, and the price-to-book ratio stands at 5.21.

As of June 30, 2026, Pharma Mar SA trades at an EV/EBITDA multiple of 16.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.79 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.18B versus a market cap of 1.31B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pharma Mar SA maintains a current ratio of 2.85, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.28, indicating elevated leverage, while an interest coverage ratio of 35.74 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharma Mar SA posted a return on equity (ROE) of 35.47, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 21.87, measuring how efficiently the asset base is converted into earnings. Inventory turnover of 0.37 indicates how many times Pharma Mar SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pharma Mar SA recorded an income tax benefit of -15.34M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 64.16M, leaving 79.50M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Pharma Mar SA's stock has declined approximately 6.73% over the past 52 weeks. The 50-day moving average sits at 75.91, while the 200-day moving average is 82.32.

Over the twelve months ended June 30, 2026, Pharma Mar SA generated 277.23M in revenue and converted that into 79.50M in net income, yielding earnings per share of 4.57. EBITDA reached 71.23M, while operating income came in at 62.21M.

As of June 30, 2026, Pharma Mar SA holds 168.88M in cash and equivalents against 45.84M in total debt, resulting in a net debt position of 23.71M. Total book value stands at 250.78M, with working capital of 182.53M providing operational flexibility.

Pharma Mar SA produced 54.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.08M in capital expenditures, free cash flow totaled 49.60M - equivalent to 2.85 per share.

Over the twelve months ended June 30, 2026, Pharma Mar SA posted a gross margin of 93.27, reflecting its pricing power and cost economics. The operating margin of 22.44 and net profit margin of 28.68 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Pharma Mar SA paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.78, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.66, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pharma Mar SA shareholders.

Pharma Mar SA's most recent stock split took place on July 22, 2020 with a 12:1 split ratio.

As of June 30, 2026, Pharma Mar SA has an Altman Z-Score of 8.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.